Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156042 | 0.90 | ADORA2A (0.79) | ADORA2ANAMPT | |
| SCHEMBL8247550 | 0.89 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL8249497 | 0.88 | ADORA2A (0.80) | ADORA2AALDH1A1KDM4EGAAHPGD | |
| SCHEMBL8245706 | 0.87 | ADORA2A (0.63) | ADORA2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL8246979 | 0.85 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL8250305 | 0.85 | ADORA2A (0.62) | ADORA2A | |
| SCHEMBL8247557 | 0.84 | ADORA2A (0.61) | ADORA2A | |
| SCHEMBL8245612 | 0.84 | ADORA2A (0.73) | ADORA2AALDH1A1KDM4EGAAHPGD | |
| SCHEMBL8245590 | 0.83 | ADORA2A (0.59) | ADORA2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL8247473 | 0.83 | ADORA2A (0.63) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007022305-A2 | 2-AMINOIMIDAZOPYRIDINES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |